GlassScriptPhysician profile
Lauren E Leuck
NPI 1245796655
$1,474.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $837 · 2024: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $359.34 | 2023-2024 | Sotyktu |
| Abbvie INC. | $329.67 | 2023-2024 | |
| Genzyme Corporation | $155.36 | 2022-2024 | |
| Janssen Biotech, INC. | $104.01 | 2023-2024 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $97.61 | 2023-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $94.08 | 2023-2024 | Dupixent, Libtayo |
| Incyte Corporation | $85.60 | 2023 | Opzelura |
| Ucb, INC. | $51.92 | 2023-2024 | Bimzelx, Cimzia |
| Alexion Pharmaceuticals, INC. | $49.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $48.31 | 2022 | |
| Galderma Laboratories, L.P. | $42.39 | 2023 | Aklief, Oracea |
| Pfizer INC. | $42.09 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Leuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.